Pham Quang X sold $13K of CVKD
Pham Quang X (Chairman, CEO and Interim CFO) sold 4,126 shares of Cadrenal Therapeutics, Inc. (CVKD) at an average of $3.18 ($3.16–$3.18) across 2 trades over 2026-06-16 to 2026-06-17 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Top executive (Chairman/CEO/Interim CFO) executed an open-market sale of 4,126 shares across two days at about $3.17 average, under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor for additional insider activity, but this specific disclosure is unlikely to drive a fundamental repricing by itself.
What to watch
The filing doesn’t disclose reasons for sale beyond plan structure; without concurrent fundamentals (guidance, trial updates, financing), the trading signal is mostly sentiment/positioning rather than fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Cadrenal Therapeutics, Inc. (CVKD).
Ticker impact
CVKD insider Form 4 shows CEO/Chairman sold 4,126 shares in open-market trades at ~$3.16–$3.18 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless accompanied by other negative news.
The filing is primary-source and time-stamped, but the transaction is small relative to typical company size and explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretive weight.
Market effects
No sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because it’s a pre-arranged 10b5-1 plan, the sale may be mechanically scheduled and not a bearish signal; traders may ignore it unless follow-on selling accelerates.
Key entities
- issuerCadrenal Therapeutics, Inc.
Subject of the Form 4 insider transaction; ticker CVKD.
- insiderPham Quang X
Chairman, CEO and Interim CFO; reported open-market sale under 10b5-1 plan.
